Skip to main content

Advertisement

SpringerLink
Log in

Gluten ataxia and post-streptococcal central nervous system syndromes: Emerging immune-mediated disorders of the central nervous system?

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

There is an “emerging concept” that central nervous system dysfunction can be caused by an aberrant immune response triggered by exogenous antigens such as the food allergen gluten or streptococcal infection. The hypothesis of a gluten sensitive ataxia remains unproven, but is worthy of consideration. The data in support of this hypothesis require critical review before any treatment recommendations can be formulated. The idea that anti-gliadin antibody seropositivity per se justifies the term “gluten sensitivity” is important because it offers potential therapeutic possibilities, including simple exclusion diets, for patients with antigliadin antibody-associated ataxia. Post-streptococcal basal ganglia dysfunction has various manifestations, all of which fall into a relatively well-defined symptom complex or syndrome. Anti-basal ganglia antibodies that are associated with serologic evidence of recent streptococcal infection are a potential diagnostic marker for this group of disorders, which includes Sydenham’s chorea (SC) as the prototype. More recently subjects with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, Tourette’s syndrome, obsessive-compulsive disorder and other movement disorders have been described in association with anti-basal ganglia antibodies. The apparent overlap between the clinical phenotype of SC, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, Tourette’s syndrome, and obsessive-compulsive disorder suggests that they may represent one disease entity. The current working hypothesis is that antibodies induced in response to streptococcal infection cross-react with antigenic determinants in the basal ganglia resulting in basal ganglia dysfunction. Although the experimental evidence is incomplete, there is sufficient evidence to support immune-mediated basal ganglia dysfunction as an emerging clinical entity. This has important implications for the diagnosis and treatment of subjects with these disorders. The latter includes the judicious use of anti-biotic prophylaxis and immunomodulatory therapies. Apart from the diagnosis and management of SC, no consensus exists regarding the diagnosis and management of the other clinical entities within this group of disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wills AJ, Unsworth DJ: The neurology of gluten sensitivity: separating the wheat from the chaff. Curr Opin Neurol 2002, 15:519–523.

    Article  PubMed  Google Scholar 

  2. Cook HB, Burt MJ, Collett JA, et al.: Adult coeliac disease: prevalence and clinical significance. J Gastroenterol Hepatol 2000, 15:1032–1036.

    Article  PubMed  CAS  Google Scholar 

  3. Leonard J, Haffenden G, Tucker W, et al.: Gluten challenge in dermatitis herpetiformis. N Engl J Med 1983, 308:816–819.

    Article  PubMed  CAS  Google Scholar 

  4. Lock RJ, Gilmour JE, Unsworth DJ: Anti-tissue trans-glutaminase, anti-endomysium and anti-R1-reticulin autoantibodies-the antibody trinity of coeliac disease. Clin Exp Immunol 1999, 116:25–262.

    Article  Google Scholar 

  5. Hadjivassiliou M, Gibson A, Davies-Jones GA, et al.: Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996, 347:369–371.

    Article  PubMed  CAS  Google Scholar 

  6. Cooke WT, Smith WT: Neurological disorders associated with adult coeliac disease. Brain 1966, 89:683–722.

    Article  PubMed  CAS  Google Scholar 

  7. Hermaszewski RA, Rigby S, Dalgleish AG: Coeliac disease presenting with cerebellar degeneration. Postgrad Med J 1991, 67:1023–1024.

    PubMed  CAS  Google Scholar 

  8. Collin P, Pirttila T, Nurmikko T, et al.: Celiac disease, brain atrophy, and dementia. Neurology 1991, 41:372–375.

    PubMed  CAS  Google Scholar 

  9. Kaplan JG, Pack D, Horoupian D, et al.: Distal axonopathy associated with chronic gluten enteropathy: a treatable disorder. Neurology 1988, 38:642–645.

    PubMed  CAS  Google Scholar 

  10. Pereira AC, Edwards MJ, Buttery PC, et al.: Choreic syndrome and coeliac disease: a hitherto unrecognised association. Mov Disord 2004, 19:478–482.

    Article  PubMed  Google Scholar 

  11. Hadjivassiliou M, Grunewald R, Sharrack B, et al.: Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain 2003, 126:685–691.

    Article  PubMed  Google Scholar 

  12. Combarros O, Infante J, Lopez-Hoyos M, et al.: Celiac disease and idiopathic cerebellar ataxia. Neurology 2000, 54:2346.

    PubMed  CAS  Google Scholar 

  13. Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallett M: Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001, 49:540–543.

    Article  PubMed  CAS  Google Scholar 

  14. Bushara KO, Nance M, Gomez CM: Antigliadin antibodies in Huntington’s disease. Neurology 2004, 62:132–133.

    PubMed  Google Scholar 

  15. Pellecchia MT, Ambrosio G, Salvatore E, et al.: Possible gluten sensitivity in multiple system atrophy. Neurology 2002, 59:1114–1115.

    PubMed  CAS  Google Scholar 

  16. Pengiran Tengah CD, Lock RJ, et al.: Multiple sclerosis and occult gluten sensitivity. Neurology 2004, 62:2326–2327.

    PubMed  Google Scholar 

  17. Hadjivassiliou M, Boscolo S, Davies-Jones GA, et al.: The humoral response in the pathogenesis of gluten ataxia. Neurology 2002, 58:1221–1226.

    PubMed  CAS  Google Scholar 

  18. Chinnery PF, Reading PJ, Milne D, et al.: CSF antigliadin antibodies and the Ramsay Hunt syndrome. Neurology 1997, 49:1131–1133.

    PubMed  CAS  Google Scholar 

  19. Archelos JJ, Hartung HP: Pathogenetic role of auto-antibodies in neurological diseases. Tre nds Ne ur o s c i 2000, 23:317–327.

    CAS  Google Scholar 

  20. Mercadante MT, Busatto GF, Lombroso PJ, et al.: The psychiatric symptoms of rheumatic fever. Am J Psychiatry 2000, 157:2036–2038.

    Article  PubMed  CAS  Google Scholar 

  21. Cardoso F, Eduardo C, Silva AP, Mota CC: Chorea in fifty consecutive patients with rheumatic fever. Mov Disord 1997, 12:701–703.

    Article  PubMed  CAS  Google Scholar 

  22. Swedo SE, Leonard HL, Garvey M, et al.: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998, 155:264–271.

    PubMed  CAS  Google Scholar 

  23. Dale RC, Church AJ, Surtees RAH, et al.: Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004, 127:21–33. This paper describes post-streptococcal encephalitis lethargica-like syndrome in association with ABGA. The findings support the hypothesis that the original encephalitis lethargica epidemic may have been triggered by a streptococcal infection.

    Article  PubMed  Google Scholar 

  24. Dale RC, Heyman I, Surtees RAH, et al.: Dyskinesias and associated psychiatric disorders following streptococcal infections. Arch Dis Child 2004, 89:604–610.

    Article  PubMed  CAS  Google Scholar 

  25. Edwards MJ, Dale RC, Church AJ, et al.: A dystonic syndrome associated with antibasal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004, 75:914–916. This is a cross-sectional study showing that post-streptococcal CNS syndromes are not limited to children and the phenotype is wider than previously expected.

    Article  PubMed  CAS  Google Scholar 

  26. Swedo SE, Leonard HL, Rapoport JL: The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics 2004, 113:907–911.

    Article  PubMed  Google Scholar 

  27. Kurlan R, Kaplan EL: The pediatric autoimmune neuropsychiatric disorders associated with strepto-coccal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? Practical considerations for the clinician. Pediatrics 2004, 113:883–886.

    Article  PubMed  Google Scholar 

  28. Church AJ, Dale RC, Lees AJ, et al.: Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry 2003, 74:602–607.

    Article  PubMed  CAS  Google Scholar 

  29. Loiselle CR, Wendlandt JT, Rohde CA, Singer HS: Anti-streptococcal, neuronal, and nuclear antibodies in Tourette syndrome. Pediatr Neurol 2003, 28:119–125.

    Article  PubMed  Google Scholar 

  30. Greenfield JG, Wolfsohn JM: The pathology of Sydenham’s chorea. Lancet 1922, 2:603–606.

    Article  Google Scholar 

  31. Giedd JN, Rapoport JL, Garvey MA, et al.: MRI assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection. Am J Psychiatry 2000, 157:281–283.

    Article  PubMed  CAS  Google Scholar 

  32. Martino D, Giovannoni G: Antibasal ganglia antibodies and their relevance to movement disorders. Curr Opin Neurol 2004, 17:425–432.

    Article  PubMed  Google Scholar 

  33. Husby G, van de Rijn I, Zabriskie JB, Abdin ZH, Williams RC Jr. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976, 144:1094–110.

    Article  PubMed  CAS  Google Scholar 

  34. Singer HS, Loiselle CR, Lee O, et al.: Antibasal ganglia antibody abnormalities in Sydenham chorea. J Neuroimmunol 2003, 136:154–161.

    Article  PubMed  CAS  Google Scholar 

  35. Singer HS, Loiselle CR, Lee O, et al.: Anti-basal ganglia antibodies in PANDAS. Mov Disord 2004, 19:406–415.

    Article  PubMed  Google Scholar 

  36. Church AJ, Cardoso F, Dale RC, et al.: Anti-basal ganglia antibodies in acute and persistent Sydenham’s chorea. Neurology 2002, 59:227–231.

    PubMed  CAS  Google Scholar 

  37. Hallett JJ, Harling-Berg CJ, Knopf PM, et al.: Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol 2000, 111:195–202.

    Article  PubMed  CAS  Google Scholar 

  38. Taylor JR, Morshed SA, Parveen S, et al.: An animal model of Tourette’s syndrome. Am J Psychiatry 2002, 159:657–660.

    Article  PubMed  Google Scholar 

  39. Loiselle CR, Lee O, Moran TH, Singer HS: Striatal microinfusion of Tourette syndrome and PANDAS sera: failure to induce behavioral changes. Mov Disord 2004, 19:390–396.

    Article  PubMed  Google Scholar 

  40. Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grunewald RA: Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003, 74:1221–1224. This preliminary study suggested that gluten ataxia may responds to a strict GFD in the absence of an enteropathy. This study needs to be confirmed in randomized, single-blind studies.

    Article  PubMed  CAS  Google Scholar 

  41. Lu CS, Thompson PD, Quinn NP, et al.: Ramsay Hunt syndrome and coeliac disease: a new association? Mov Disord 1986, 1:209–219.

    Article  PubMed  CAS  Google Scholar 

  42. Battisti C, Dotti MT, Formichi P, et al.: Disappearance of skin lipofuscin storage and marked clinical improvement in adult onset coeliac disease and severe vitamin E deficiency after chronic vitamin E megatherapy. J Submicrosc Cytol Pathol 1996, 28:339–334.

    PubMed  CAS  Google Scholar 

  43. Mauro A, Orsi L, Mortara P, et al.: Cerebellar syndrome in adult celiac disease with vitamin E deficiency. Acta Neurol Scand 1991, 84:167–170.

    Article  PubMed  CAS  Google Scholar 

  44. Ghezzi A, Filippi M, Falini A, Zaffaroni M: Cerebral involvement in celiac disease: a serial MRI study in a patient with brainstem and cerebellar symptoms. Neurology 1997, 49:1447–1450.

    PubMed  CAS  Google Scholar 

  45. Rush PJ, Inman R, Bernstein M, et al.: Isolated vasculitis of the central nervous system in a patient with celiac disease. Am J Med 1986, 81:1092–1094.

    Article  PubMed  CAS  Google Scholar 

  46. Beyenburg S, Scheid B, Deckert-Schluter M, Lagreze HL: Chronic progressive leukoencephalopathy in adult celiac disease. Neurology 1998, 50:820–822.

    PubMed  CAS  Google Scholar 

  47. Burk K, Melms A, Schulz JB, Dichgans J: Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 2001, 50:827–828.

    Article  PubMed  CAS  Google Scholar 

  48. Dajani AS, Bisno AL, Chung KJ, et al.: Prevention of rheumatic fever: a statement for health professionals by the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the young, the American Heart Association. Pediatr Infect Dis J 1989, 8:263–266.

    PubMed  CAS  Google Scholar 

  49. National guidelines on primary prevention and prophylaxis of rheumatic fever (RF) and rheumatic heart disease (RHD) for health professionals at primary level. http://www.doh.gov.za/docs/factsheets/guidelines/ rheuma.pdf (Accessed December 14, 2004)

  50. Garvey MA, Perlmutter SJ, Allen AJ, et al.: A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry 1999, 45:1564–1571.

    Article  PubMed  CAS  Google Scholar 

  51. Murphy ML, Pichichero ME: Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adolesc Med 2002, 156:356–361.

    PubMed  Google Scholar 

  52. Snider LA, Lougee L, Slattery M, et al.: Antibiotic prophylaxis against Group A Betahemolytic Streptococci with azithromycin or penicillin for childhoodonset neuropsychiatric disorders. In Press.

  53. Garvey MA, Swedo SE, Shapiro MB, et al.: Intravenous immunoglbulin and plasmapheresis as effective treatments of Sydenham’s chorea. Neurology 1996, 46(Suppl):A147.

    Google Scholar 

  54. Green LN: Corticosteroids in the treatment of Sydenham’s chorea. Arch Neurol 1978, 35:53–54.

    PubMed  CAS  Google Scholar 

  55. Cardoso F, Maia D, Cunningham MC, Valenca G: Treatment of Sydenham chorea with corticosteroids. Mov Disord 2003, 18:1374–1377.

    Article  PubMed  Google Scholar 

  56. Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153–1158. This was the first single-blinded, randomized trial of plasma exchange and IVIg in subjects with PANDAS. This study is important because it highlights the methodologic difficulties of doing trials in children with PANDAS.

    Article  PubMed  CAS  Google Scholar 

  57. Nicolson R, Swedo SE, Lenane M, et al.: JL. An open trial of plasma exchange in childhood-onset obsessive-compulsive disorder without poststreptococcal exacerbations. J Am Acad Child Adolesc Psychiatry 2000, 39:1313–1315.

    Article  PubMed  CAS  Google Scholar 

  58. Pena J, Mora E, Cardozo J, et al.: Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham’s chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr 2002, 60:374–377.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Neurology, Queen Square, WC1 3BG, London, UK

    Gavin Giovannoni MB, BCh, PhD

Authors
  1. Adrian Wills MB, BS, MRCP, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Dale MBChB, MRCHP, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gavin Giovannoni MB, BCh, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wills, A., Dale, R. & Giovannoni, G. Gluten ataxia and post-streptococcal central nervous system syndromes: Emerging immune-mediated disorders of the central nervous system?. Curr Treat Options Neurol 7, 183–189 (2005). https://doi.org/10.1007/s11940-005-0011-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-005-0011-5

Keywords

Search

Navigation